- Home
- ICLR vs BAX Comparison
ICLR vs BAX Comparison
Compare ICLR & BAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICLR
- BAX
- Stock Information
- Founded
- ICLR 1990
- BAX 1931
- Country
- ICLR Ireland
- BAX United States
- Employees
- ICLR N/A
- BAX N/A
- Industry
- ICLR Biotechnology: Commercial Physical & Biological Resarch
- BAX Medical/Dental Instruments
- Sector
- ICLR Health Care
- BAX Health Care
- Exchange
- ICLR Nasdaq
- BAX Nasdaq
- Market Cap
- ICLR 13.7B
- BAX 12.4B
- IPO Year
- ICLR 1998
- BAX N/A
- Fundamental
- Price
- ICLR $186.17
- BAX $22.99
- Analyst Decision
- ICLR Buy
- BAX Hold
- Analyst Count
- ICLR 15
- BAX 9
- Target Price
- ICLR $210.64
- BAX $30.78
- AVG Volume (30 Days)
- ICLR 1.0M
- BAX 6.1M
- Earning Date
- ICLR 10-22-2025
- BAX 11-07-2025
- Dividend Yield
- ICLR N/A
- BAX 2.97%
- EPS Growth
- ICLR 13.11
- BAX N/A
- EPS
- ICLR 9.73
- BAX N/A
- Revenue
- ICLR $8,089,820,000.00
- BAX $10,887,000,000.00
- Revenue This Year
- ICLR N/A
- BAX $7.39
- Revenue Next Year
- ICLR $1.42
- BAX $3.79
- P/E Ratio
- ICLR $19.56
- BAX N/A
- Revenue Growth
- ICLR N/A
- BAX 3.60
- 52 Week Low
- ICLR $125.10
- BAX $21.33
- 52 Week High
- ICLR $303.69
- BAX $38.29
- Technical
- Relative Strength Index (RSI)
- ICLR 59.53
- BAX 45.26
- Support Level
- ICLR $161.70
- BAX $21.59
- Resistance Level
- ICLR $197.05
- BAX $24.27
- Average True Range (ATR)
- ICLR 6.49
- BAX 0.61
- MACD
- ICLR 2.00
- BAX 0.14
- Stochastic Oscillator
- ICLR 70.56
- BAX 51.59
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
About BAX Baxter International Inc.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.